Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with bevacizumab (BEV)-refractory recurrent glioblastoma (GBM) Meeting Abstract
| Authors: | Reardon, D.; Kaley, T.; Dietrich, J.; Clarke, J. L.; Dunn, G. P.; Lim, M.; Cloughesy, T.; Gan, H. K.; Park, A.; Schwarzenberger, P.; Ricciardi, T.; Macri, M.; Ryan, A.; Venhaus, R. |
| Abstract Title: | Phase 2 study to evaluate the clinical efficacy and safety of MEDI4736 (durvalumab [DUR]) in patients with bevacizumab (BEV)-refractory recurrent glioblastoma (GBM) |
| Meeting Title: | 22nd Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) |
| Journal Title: | Neuro-Oncology |
| Volume: | 19 |
| Issue: | Suppl. 6 |
| Meeting Dates: | 2017 Nov 16-19 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 1522-8517 |
| Publisher: | Oxford University Press |
| Date Published: | 2017-01-01 |
| Start Page: | vi28 |
| Language: | English |
| ACCESSION: | WOS:000415152500109 |
| PROVIDER: | wos |
| DOI: | 10.1093/neuonc/nox168.108 |
| PMCID: | PMC5692026 |
| Notes: | Meeting Abstract: ATIM-12 -- Joint Conference of 22nd Annual Scientific Meeting and Education Day of the Society-for-Neuro-Oncology / Conference of the Society-for-CNS-Interstitial-Delivery-of-the-Therapeutics (SCIDOT) on Therapeutic Delivery to the CNS -- NOV 15-19, 2017 -- San Francisco, CA -- Source: Wos |
